Kaku A So-Armah1, E Jennifer Edelman2, Debbie M Cheng3, Margaret F Doyle4, Gregory J Patts3, Natalia Gnatienko1, Evgeny M Krupitsky5, Jeffrey H Samet1, Matthew S Freiberg6. 1. Boston University School of Medicine/Boston Medical Center, Boston, Massachusetts. 2. Yale University School of Medicine, New Haven, Connecticut. 3. Boston University School of Public Health, Boston, Massachusetts. 4. University of Vermont College of Medicine, Burlington, Vermont. 5. St.-Petersburg Bekhterev Research Psychoneurological Institute, Pavlov State Medical University, St. Petersburg, Russia. 6. Vanderbilt University School of Medicine, Nashville, Tennessee.
Abstract
BACKGROUND: The role of alcohol consumption in HIV-related adaptive immune dysfunction is debated. We hypothesized that heavy drinking would be associated with greater evidence of immunosenescence (i.e., aging-related decline of adaptive immune function) among antiretroviral therapy (ART)-naïve HIV-infected individuals. METHODS: Using data from the Russia ARCH cohort study, we conducted a cross-sectional analysis of ART-naïve HIV-infected individuals recruited between 2012 and 2014. INDEPENDENT VARIABLE: Heavy drinking defined as >4 standard drinks in a day (or >14 standard drinks per week) for men and >3 per day (or >7 per week) for women, respectively. DEPENDENT VARIABLES: Percentage of CD8+ and CD4+ T-cells with a phenotype consistent with immunosenescence (i.e., expressing CD28- CD57+, or memory [CD45RO+ CD45RA+] phenotype and not the naïve [CD45RO- CD45RA+] phenotype). STATISTICAL ANALYSIS: Multiple linear regression adjusted for confounders. RESULTS: Of 214 eligible participants, 61% were heavy drinkers. Mean age was 33 years and the cohort was predominantly male (72%). Hepatitis C prevalence was high (87%) and mean log10 HIV-1 RNA copies/ml was 4.6. We found no significant differences by drinking status in the percentage of immunosenescent, memory, or naïve CD8+ or CD4+ T-cells. CONCLUSIONS: In this cross-sectional analysis, heavy drinking in the setting of untreated HIV infection did not appear to be associated with alterations in T-cell phenotypes consistent with immunosenescence. To substantiate these findings, longitudinal studies should assess whether changes in alcohol consumption are associated with changes in these and other immunosenescent T-cell phenotypes.
BACKGROUND: The role of alcohol consumption in HIV-related adaptive immune dysfunction is debated. We hypothesized that heavy drinking would be associated with greater evidence of immunosenescence (i.e., aging-related decline of adaptive immune function) among antiretroviral therapy (ART)-naïve HIV-infected individuals. METHODS: Using data from the Russia ARCH cohort study, we conducted a cross-sectional analysis of ART-naïve HIV-infected individuals recruited between 2012 and 2014. INDEPENDENT VARIABLE: Heavy drinking defined as >4 standard drinks in a day (or >14 standard drinks per week) for men and >3 per day (or >7 per week) for women, respectively. DEPENDENT VARIABLES: Percentage of CD8+ and CD4+ T-cells with a phenotype consistent with immunosenescence (i.e., expressing CD28- CD57+, or memory [CD45RO+ CD45RA+] phenotype and not the naïve [CD45RO- CD45RA+] phenotype). STATISTICAL ANALYSIS: Multiple linear regression adjusted for confounders. RESULTS: Of 214 eligible participants, 61% were heavy drinkers. Mean age was 33 years and the cohort was predominantly male (72%). Hepatitis C prevalence was high (87%) and mean log10 HIV-1 RNA copies/ml was 4.6. We found no significant differences by drinking status in the percentage of immunosenescent, memory, or naïve CD8+ or CD4+ T-cells. CONCLUSIONS: In this cross-sectional analysis, heavy drinking in the setting of untreated HIV infection did not appear to be associated with alterations in T-cell phenotypes consistent with immunosenescence. To substantiate these findings, longitudinal studies should assess whether changes in alcohol consumption are associated with changes in these and other immunosenescent T-cell phenotypes.
Authors: F A Arosa; G Porto; J M Cabeda; R Lacerda; D Resende; E Cruz; C Cardoso; M Fonseca; C Simões; P Rodrigues; F Bravo; J C Oliveira; H Alves; J Fraga; B Justiça; M de Sousa Journal: Alcohol Clin Exp Res Date: 2000-04 Impact factor: 3.455
Authors: Jason M Brenchley; Nitin J Karandikar; Michael R Betts; David R Ambrozak; Brenna J Hill; Laura E Crotty; Joseph P Casazza; Janaki Kuruppu; Stephen A Migueles; Mark Connors; Mario Roederer; Daniel C Douek; Richard A Koup Journal: Blood Date: 2002-11-14 Impact factor: 22.113
Authors: Amy C Justice; Elizabeth Dombrowski; Joseph Conigliaro; Shawn L Fultz; Deborah Gibson; Tamra Madenwald; Joseph Goulet; Michael Simberkoff; Adeel A Butt; David Rimland; Maria C Rodriguez-Barradas; Cynthia L Gibert; Kris Ann K Oursler; Sheldon Brown; David A Leaf; Matthew B Goetz; Kendall Bryant Journal: Med Care Date: 2006-08 Impact factor: 2.983
Authors: Maria Cecilia G Marcondes; Debbie Watry; Michelle Zandonatti; Claudia Flynn; Michael A Taffe; Howard Fox Journal: Alcohol Clin Exp Res Date: 2008-07-09 Impact factor: 3.455
Authors: Anna Conen; Qing Wang; Tracy R Glass; Christoph A Fux; Maria C Thurnheer; Christina Orasch; Alexandra Calmy; Enos Bernasconi; Pietro Vernazza; Rainer Weber; Heiner C Bucher; Manuel Battegay; Jan Fehr Journal: J Acquir Immune Defic Syndr Date: 2013-12-15 Impact factor: 3.731
Authors: Laura F White; Wenqing Jiang; Yicheng Ma; Kaku So-Armah; Jeffrey H Samet; Debbie M Cheng Journal: Drug Alcohol Depend Date: 2020-02-27 Impact factor: 4.492
Authors: Judith I Tsui; Stephen C Ko; Evgeny Krupitsky; Dmitry Lioznov; Christine E Chaisson; Natalia Gnatienko; Jeffrey H Samet Journal: Hepatol Med Policy Date: 2016-10-11